While serum FGF19 is considered as a potential novel biomarker for HCC [43], it appears that serum FGF19 may not help improve the prognosis in HNSCC patients as there is no statistical difference in serum FGF19 between patients and healthy controls. Here, FGF19 is linked to head and neck squamous cell carcinoma.